Lenti HPV 07
Alternative Names: Lenti-HPV-07Latest Information Update: 08 Apr 2024
At a glance
- Originator THERAVECTYS
- Developer Institut Pasteur; THERAVECTYS
- Class Dendritic cell vaccines; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Human papillomavirus infections
Most Recent Events
- 08 Aug 2024 Phase-I/II clinical trials in Human papillomavirus infections in USA (IM) (Theravectys pipeline, April 2024)
- 08 Apr 2024 Lenti HPV 07 is available for licensing as of 08 Apr 2024. https://www.theravectys.com/partnerships/ (TheraVectys website, April 2024)
- 22 Mar 2024 Preclinical trials in Human papillomavirus infections in France (IM) prior to March 2024